STERLING's INOCOR (AMRINONE) I.V. IS "APPROVABLE"
STERLING's INOCOR (AMRINONE) I.V. IS "APPROVABLE" the company announced in a May 23 press release. The drug will be marketed to U.S. physicians and hospitals by Sterling's Winthrop-Breon Labs pending FDA approval of labeling and packaging information. Sterling said that Inocor I.V. will be used in hospitals among patients with severe congestive heart failure unresponsive to other therapies. The release describes amrinone as an "inotropic agent which improves directly the pumping force of the heart and serves simultaneously as a mild dilator of the blood vessels." The approval of the I.V. form of amrinone follows in the wake of Sterling's decision in January to halt clinical studies on the oral form of the drug because of a high incidence of gastro-intestinal side effects (The Pink Sheet" Jan. 23, T&G-2). In October 1982, FDA's Cardio-Renal Drugs Advisory Cmte. declined to recommend approval of oral amrinone until Sterling completed an additional long-term clinical study. However, after preliminary review of the study showed that the high incidence of gastrointestinal side effects was causing a drop out rate that would make it difficult to establish statistical significance of efficacy, Sterling made the decision to halt work on the oral drug. The company has not withdrawn its pending NDA from FDA on that form, however. Along with the announcement in January of its decision to halt the clinical study with oral amrinone, Sterling said that it intended to "accelerate both oral and intravenous studies on milrinone," an analogue of amrinone also for the treatment of congestive heart failure. Sterling noted that preliminary clinical studies have show that milrinone "is 10 to 30 times more potent than amrionone, Sterling's first inotropic discovery, and has been remarkably free of side effects." The company said that milrinone "has entered expanded clinical trials for both oral and intravenous dosage forms. Results with both forms appear encouraging."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth